On June 28, 2012, KangLaiTe-USA presented interim data on its clinical candidate, Kanglaite Injection (KLTi), at the Multinational Association of Supportive Care in Cancer Annual Conference in Boston, Massachusetts. The Phase II clinical trial results included 41 patients with advanced pancreatic cancer who were given gemcitabine with or without Kanglaite Injection (KLTi) to assess the investigational product’s effect on outcome. For more information, please refer to the Publications page.
Creating A New Vision In Cancer Treatment
